ODTX

16.8658.04%
SC

Stephen C. Blacklow

Chairman of Scientific Advisory Board

Dr. Stephen C. Blacklow, MD, PhD, serves as Member of Scientific Advisory Board at Erasca, Inc. He serves as Member of Medical and Scientific Advisory Board and was an Advisor at MPM Asset Management, L.L.C. Dr. Blacklow is the Chairman of Scientific Advisory Board at Odyssey Therapeutics, Inc since September 2024. Dr. Blacklow serves as an Associate Professor of Pathology and a Director of the MD, PhD program and basic sciences track, at Harvard Medical School. Dr. Blacklow also directs a research laboratory at the Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School. Over the last ten years, his research team has achieved international recognition for mechanistic and structural studies of low-density lipoprotein or LDL receptor proteins and for work on the structure and function of human Notch proteins. Dr. Blacklow contributes scientific expertise from academia to Horizon’s scientific advisory board, where he has been a Member of Scientific Advisory Board of Horizon Pharmaceutical LLC since July 2008. He is a world expert in SHP2 who helped pioneer development of the first SHP2 inhibitor with Novartis and is the Gustavus Adolphus Pfeiffer Professor of Biological Chemistry and Molecular Pharmacology, Biological Chemistry and Molecular Pharmacology at Harvard Medical School; a Professor of Pathology at the Brigham And Women’s Hospital; a Professor of Cancer Biology at the Dana-Farber Cancer Institute; and the Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Dr. Blacklow received his MD and PhD in Bioorganic Chemistry from Harvard University in 1991.

Positions